Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IOBT - IO Biotech Inc


IEX Last Trade
1.48
-0.060   -4.054%

Share volume: 973,657
Last Updated: Fri 30 Aug 2024 09:30:12 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.54
-0.06
-3.90%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-8.54%
1 Month
13.64%
3 Months
20.97%
6 Months
-1.96%
1 Year
-20.63%
2 Year
-56.27%
Key data
Stock price
$1.48
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.82 - $2.10
52 WEEK CHANGE
-$0.17
MARKET CAP 
98.821 M
YIELD 
N/A
SHARES OUTSTANDING 
65.881 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
1.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$254,415
AVERAGE 30 VOLUME 
$178,710
Company detail
CEO:
Region: US
Website: iobiotech.com
Employees: 55
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

io biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of t cells that are specific for immune inhibitory molecules. io biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting ido and pd-l1 in clinical development and several compounds finalizing preclinical phase. io biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

Recent news